Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2512]

ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

ESMO 2016: Custirsen shows no survival benefits in metastatic prostate cancer

ESMO 2016: Custirsen shows no survival benefits in metastatic prostate cancer

ESMO 2016: Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

ESMO 2016: Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

Scientists find lethal vulnerability in treatment-resistant lung cancer

Scientists find lethal vulnerability in treatment-resistant lung cancer

Bladder cancer research rife with new approaches

Bladder cancer research rife with new approaches

Intensity modulated pelvic radiation therapy reduces patient reported toxicities

Intensity modulated pelvic radiation therapy reduces patient reported toxicities

ASTRO 2016: Radiation therapy and radical prostatectomy explored further for initial diagnosis of advanced prostate cancer

ASTRO 2016: Radiation therapy and radical prostatectomy explored further for initial diagnosis of advanced...

$ASTRO 2016: Hypofractionated radiotherapy for prostate cancer can reduce treatment time by one-third with comparable QOL$

ASTRO 2016: Hypofractionated radiotherapy for prostate cancer can reduce treatment time by one-third with...

ASTRO 2016: Intermediate risk prostate cancer may be well controlled with brachytherapy alone

ASTRO 2016: Intermediate risk prostate cancer may be well controlled with brachytherapy alone

More from ecancer